UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of June 2015
001-37353
(Commission File Number)
BIONDVAX PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in its charter)
14 Einstein St.
Nes Ziona
Israel 74036
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ Noþ
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A
Below is an English translation (from Hebrew) from an immediate report by BiondVax Pharmaceuticals Ltd. as published on the Tel-Aviv Stock Exchange Ltd. and the Israeli Securities Authority on June 7, 2015, in accordance with the Israeli Security Regulations.
Name of holder
IBI Investment House Ltd. – Market maker
The name in English
IBI Investment House Ltd.
Type of holder: Market maker
ID type: Registration number in the Israel Companies Registrar: 520034356
Nationality / country of incorporation or registration: Incorporated in Israel
Does the holder serve as the representative for reporting purposes of several shareholders who, jointly with him / her / it, hold corporation securities Yes
Are the ordinary shares treasury shares No
Security no. on TASE: 1105204
Balance in the previous summary report (the amount of securities): 910
Change in the amount of securities: +7,970
Holder's maximum holding rate of the security during the reported period: 0.02%
Holder's minimum holding rate of the security during the reported period: 0.00%
Name of holder
IBI Investment House Ltd.
The name in English
IBI Investment House Ltd.
Type of holder: Management companies of mutual investment trust funds
ID type:Registration number in the Israel Companies Registrar: 520034356
Country of incorporation or registration: Incorporated in Israel
Does the holder serve as the representative for reporting purposes of several shareholders who, jointly with him / her / it, hold corporation securities Yes
Are the ordinary shares held treasury shares No
Security no. on TASE: 11054204
Balance in the previous summary report (the amount of securities): 6,607,098
Change in the amount of securities: +2,683,659
Holder's maximum holding rate of the security during the reported period: 12.17%
Holder's minimum holding rate of the security during the reported period: 5.84%
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BiondVax Pharmaceuticals Ltd. | ||
Date: June 8, 2015 | By: | /s/ Ron Babecoff |
Ron Babecoff | ||
Chief Executive Officer |
3